news

The FFG funding agency awards Solgate a prestigious Basisprogramm grant 

Solgate GmbH announced today that it was awarded funding by the Austrian Research Promotion Agency (FFG) as part of the agency’s Basisprogramm, which aims to support innovative companies in the development of a product with commercial potential. Within this six-figure, three-year program, Solgate will leverage this funding to implement and further develop its technological platform tailored to solute carriers (SLCs), which employs cell-based scalable assays to identify novel chemical matters targeting transporters implicated in disease, with a particular focus on neurological, autoimmune, and metabolic disorders. 

Through this FFG funding, Solgate will expand its team and experimental capabilities to tackle multiple SLC targets and obtain proof-of concept data to enable the development of an internal pipeline of drug discovery programs with strong commercial potential.

For more information, contact: office@solgate.com

Solgate GmbH pursues the development of drugs modulating the activity of SLC proteins, focusing on the important roles of SLCs in neurological, autoimmune, and metabolic disorders. Through a proprietary discovery platform that combines several technologies, Solgate designs and rapidly advances novel chemical matter against selected SLCs. Solgate GmbH was founded by Ariel Bensimon, Georg Winter, Stefan Kubicek, Giulio Superti-Furga, and Gaia Novarino, together with CeMM and IST Austria.